Reducing inhaled steroid doses in people with severe asthma taking tezepelumab
Looks at lowering inhaled corticosteroids in adults with severe asthma on tezepelumab.
Plain-language title generated from the registry record
Registry title: Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes
Key facts
- Where
- Rotterdam, NetherlandsSee the site
Where in Netherlands
- Franciscus Gasthuis & VlietlandRotterdam, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Franciscus Gasthuis
- Trial code
- NCT07713498
- Record updated
- 21 July 2026
- Original description
To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world settingRead full original descriptionShow less
TITANIC - Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes
To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting
Inclusion: Age ≥18; Patient diagnosed with severe asthma according to the GINA guidelines; Written informed consent (AVG); Eligibility and willingness to present during an asthma exacerbation at the Franciscus hospital; Patient has received/or has been planned for at least one dose of tezepelumab; Sufficient understanding of the Dutch or English language.
Exclusion: Other underlying inflammatory or auto-immune diseases that require OCS treatment, such as rheumatologic disease, IBD etc; Pregnancy, because of the possible altered immunological status; Participation in an interventional study that interferes with this study.